SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV

丙型肝炎病毒 (HCV) 和 HIV 的长期抑制性抗病毒治疗

基本信息

  • 批准号:
    7717991
  • 负责人:
  • 金额:
    $ 3.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-12-01 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Objective To compare the reduction in the rate of histologic fibrosis progression from Step 2 entry to study termination between subjects treated with PEG-IFN and untreated controls in subjects with HIV-1 and hepatitis C virus (HCV) coinfection who have failed to respond to 12 weeks of PEG-IFN plus ribavirin. Secondary Objectives ¿ To evaluate the quality of life associated with long-term PEG-IFN in coinfected subjects. ¿ To determine the impact of long-term PEG-IFN use on HCV viral evolution and host immunologic response. ¿ To investigate the role of noninvasive markers of fibrosis in predicting histologic response, including ALT, AST, bilirubin, albumin, and protein. ¿ To determine the effect of long-term PEG-IFN versus untreated controls on CD4+ T-cell counts and AIDS-defining illnesses. ¿ To determine the effect of long-term PEG-IFN therapy on metabolic parameters, including body weight, lipid profile, hyperglycemia, and insulin resistance. ¿ To assess the impact of treatment on HIV disease control. ¿ To determine the influence of host genetic polymorphisms on cytokine and fibrosis-related genes on baseline histology and on histologic progression of disease.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ARDIS A MOE其他文献

ARDIS A MOE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ARDIS A MOE', 18)}}的其他基金

A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
开放标签依非韦伦或阿扎那韦联合 RI 的 IIIB 期随机试验
  • 批准号:
    7951550
  • 财政年份:
    2009
  • 资助金额:
    $ 3.16万
  • 项目类别:
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV
丙型肝炎病毒 (HCV) 和 HIV 的长期抑制性抗病毒治疗
  • 批准号:
    7951539
  • 财政年份:
    2009
  • 资助金额:
    $ 3.16万
  • 项目类别:
PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN T
米诺环素治疗 T 细胞的 II 期、随机、安慰剂对照、双盲研究
  • 批准号:
    8167100
  • 财政年份:
    2009
  • 资助金额:
    $ 3.16万
  • 项目类别:
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
开放标签依非韦伦或阿扎那韦联合 RI 的 IIIB 期随机试验
  • 批准号:
    8167085
  • 财政年份:
    2009
  • 资助金额:
    $ 3.16万
  • 项目类别:
A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF A QUADRIVALENT HUM
评估四价 HUM 免疫原性和安全性的 II 期研究
  • 批准号:
    8167119
  • 财政年份:
    2009
  • 资助金额:
    $ 3.16万
  • 项目类别:
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
开放标签依非韦伦或阿扎那韦联合 RI 的 IIIB 期随机试验
  • 批准号:
    7718009
  • 财政年份:
    2007
  • 资助金额:
    $ 3.16万
  • 项目类别:
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV
丙型肝炎病毒 (HCV) 和 HIV 的长期抑制性抗病毒治疗
  • 批准号:
    7606804
  • 财政年份:
    2007
  • 资助金额:
    $ 3.16万
  • 项目类别:
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
开放标签依非韦伦或阿扎那韦联合 RI 的 IIIB 期随机试验
  • 批准号:
    7606825
  • 财政年份:
    2007
  • 资助金额:
    $ 3.16万
  • 项目类别:
A TRIAL TO DETERMINE THE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS A
确定艾滋病发展时间的试验 定义并发症 A
  • 批准号:
    7205341
  • 财政年份:
    2004
  • 资助金额:
    $ 3.16万
  • 项目类别:
PHARMACOKINETIC EVALUATION OF THE EFFECTS OF RIBAVIRIN (RBV) ON ZIDOVUDINE (A
利巴韦林 (RBV) 对齐多夫定 (A) 作用的药代动力学评价
  • 批准号:
    7205380
  • 财政年份:
    2004
  • 资助金额:
    $ 3.16万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 3.16万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 3.16万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 3.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 3.16万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 3.16万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 3.16万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 3.16万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 3.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 3.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了